



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Flora Peyvandi**

Organisation/Company: Centro Emofilia & Trombosi Angelo Bianchi Bonomi

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

Company	Financial Interest
SANOFI	participation in advisory board
BIOMARIN	participation in advisory boards
SOBI	participation in advisory board
TAKEDA	participation in advisory board
ROCHE	participation in advisory board

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
--------	---------	----------	------------------------

Classified as public by the European Medicines Agency

01/2017-12/2021	ABLYNX BV	CAPLACIZUMAB	Thrombotic Thrombocytopenic Purpura
01/2011-12/2014	LFB	WILLFACT/WILLFACTIN	VON WILLEBRAND DISEASE
01/2015-12/2015	KEDRION BIOPHARMA	PLASMA-DERIVED FACTOR V CONCENTRATE	FV DEFICIENCY
01/2015-(current)	Baxter Innovation GmbH / BAXALTA/Takeda	rVWF	VON WILLEBRAND DISEASE
04/2011-12/2014	OCTAPHARMA AG	WILATE	VON WILLEBRAND DISEASE
03/2006-12/2016	GRIFOLS	FVIII/VWF	VON WILLEBRAND DISEASE
02/2006-12/2017	LFB-KEDRION-GRIFOLS	PLASMA DERIVED FACTOR VIII RECOMBINANT FVIII - SIPPET	HEMOPHILIA
01/2017-(current)	TAKEDA	071301-071102	rVWF
01/2018-(current)	BIOMARIN	BMN270-901/902/301	HEMOPHILIA A
01/2018-12/2021	SHIRE	201601	HEMOPHILIA
01/2017-12/2021	FREELINE	FLT-180-03/FLT180a/ECLIP SE	HEMOPHILIA B
01/2020-12/2021	CSL BEHRING	rIX-FP	FACTOR IX DEFICIENCY
01/2015-(current)	BAXALTA	ADVATE	HEMOPHILIA A
01/2016-12/2021	BAXALTA	BAX855/BAX855 PUP	Recombinant Porcine Factor VIII HEMOPHILIA A
01/2017-12/2021	BAXALTA	BAX802	Recombinant Porcine Factor VIII HEMOPHILIA A
01/2016-(current)	ROCHE	RO5534262-RO5534262	HEMOPHILIA A
01/2017-(current)	SOBI	ELOCTA	HEMOPHILIA A
01/2018-(current)	SANOFI	FITUSIRAN	HEMOPHILIA A AND B
01/2019-12/2021	BIOVERATIV	PROSPECTIVE STUDY IN SUBJECTS RECEIVING MARKETED FVIII THERAPY	HEMOPHILIA A
01/2018-12/2021	BIOVERATIV	rFVIIIc	HEMOPHILIA A
01/2018-(current)	TAKEDA	ADVATE	VWD
01/2019-(current)	TAKEDA	rADAMTS13 -BAX 930	Thrombotic Thrombocytopenic Purpura
01/2020-12/2021	TAKEDA	BAX888	HEMOPHILIA A
01/2020-(current)	SANOFI	BIVV001	SEVERE HEMOPHILIA A
01/2017-(current)	CSL BEHRING	IDELVION	HEMOPHILIA B
01/2018-12/2021	NOVO NORDISK	TUROCTOCOG (N8-GP)	HEMOPHILIA A
01/2017-(current)	NOVO NORDISK	CONCIZUMAB	HEMOPHILIA A
01/2017-12/2021	ROCHE	EMICIZUMAB	HEMOPHILIA A

2.6 Investigator

No Interest Declared

Classified as public by the European Medicines Agency

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
GRIFOLS	HEMOPHILIA
CSL BEHRING	RARE BLEEDING DISORDERS
PFIZER	RARE BLEEDING DISORDERS
SOBI	HEMOPHILIA
ROCHE HEMOPHILIA	HEMOPHILIA

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

NONE

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document

Classified as public by the European Medicines Agency

other than for the purposes of my work in connection with EMA activities.

- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Flora Peyvandi
Date:	2022-05-19

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template